YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Design of New Parenteral Aqueous Formulations of Fluconazole by the Use of Modified Cyclodextrins

시클로덱스트린류를 이용한 새로운 플루코나졸 수성 주사제의 설계

  • 이소윤 (동덕여자대학교 약학대학) ;
  • 전인구 (동덕여자대학교 약학대학)
  • Published : 2001.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study is to investigate the influence of cyclodextrins (CDs) and different acids on the solubility of fluconazole, and o formulate its more concentrated parenteral aqueous solution. Solubility studies of fluconazole with 7-CD, 2-hydroxypropyl-$\beta$-CD (HPCD), sulfobutyl ether $\beta$-CD (SBCD) and dimethyl-$\beta$-CD(DMCD) were performed. The aqueous solubility of fluconazole was measured in different concentrations of different acids with or without addition of CDs. Solubility of fluconazole increased in the rank order of $\beta$-CD$^1$H-NMR studies confirmed the formation of an inclusion complex of fluconazole with HPCD. It was also shown by the NMR studies that the complex formed was a 1:1 complex. Among the different acids used, maleic acid and phosphoric acid increased solubility of fluconazole. The lower the pH of solution is, the more fluconazole dissolved, regardless of acids. Addition of HPCD (50 mM) to acid solutions increased the solubility about two times. New fluconazole injections at a dose of 10 mg/ml could be prepared in aqueous solutions containing 10% HPCD or 15% SBCD. These parenteral solutions did not form any precipitates at 4$^{\circ}C$ and was very stable at elevated temperatures. These results demonstrate that it is possible to develop a parenteral aqueous solution of fluconazole with a smaller injection volume using HPCD or SBCD.

Keywords

References

  1. J.Chemother v.2 The discovery and profile of fluconazole Richardson,K
  2. DICP v.24 Fluconazole: a new triazole antifungal agent Pasko,M.T;Piscitelli,S.C;Van Slooten,A.D
  3. Clin.Pharm v.10 Fluconazole: a new antifungal agent Kowalsky,S.F;Dixon,D.M
  4. Drugs v.39 Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses Grant,S.M;Clissold,S.P
  5. Chemother v.39 Pharmaco-kinetics of fluconazole in normal volunteers Ripa,S;Ferrante,L;Prenna,M
  6. Clin.Pharmacokinet v.24 Clinical pharmacokinetics of fluconazole Debruyne,D;Ryckelynck,J.P
  7. Int.J.Clin.Pharmacol.Ther v.37 The uptake of fluconazole in finger and toe nails Laufen,H;Zimmermann,T;Teates,R.A;Schumacher,T;Wildfeure,A
  8. J.Pharm.Sci. v.85 Pharmaceutical applications of cyclodextrins.1.drug solubilization and stabilization Loftsson,T;Brewster,M.E
  9. J.Pharm.Sci. v.85 Pharmaceutical applications of cyclodextrins.2.In vivo drug delivery Rajewsky,R.A;Stella,V.J
  10. J.Pharm.Sci. v.82 Pharmaceutical applications of cyclodextrins.3.Toxicological issues and safety evaluation Irie,T;Uekama,K
  11. Int.J.Pharm v.46 Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrin Yoshida,A;Arima,H;Uekama,K;Pitha,J
  12. J.Parenteral Sci.Technol v.43 Development of a non-surfactant formulation for alfaxalone through the use of chemically-modified cyclodextrins Brewster,M.E;Estes,K.S;Bodor,N
  13. Int.J.Pharm. v.59 An intravenous toxicity study of hydroxypropyl-β-cyclodextrin,a useful drug solubilizer,in rats and in monkeys Brewster,M.E;Estes,K.S;Bodor,N
  14. J.Pharm.Sci. v.84 Preliminary safety evaluation of parenterally administered sulfoalkyl ether β-CD derivatives Rajewski,R.A;Traiger,G;Brenahan,J;Jaberaboansari,P;Stella,V.J;Thompson,D.O
  15. Int.J.Pharm v.169 Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins Piel.G;Evrard,B;Fillet,M;Llabres,G;Delattre,L
  16. J.Pharm.Sci v.87 Comparison of the effects of potential parenteral vehicles for poorly water soluble anti-cancer drugs(organic cosolvents and cyclodextrin solutions) on cultured endothelial cells(HUV-EC) Medlicott,N;Foster,K.A;Audus,K.L;Gupta,S;Stella,V.J
  17. In The 8th International Cyclodextrins Symposium,Programme and Abstracts Recent topics with regard to the use of Encapsin™ HPB,hydroxypropyl-β-cyclodextrin in galenical preparation Putteman,P;Caers,W;Mesens,J;Peeters,J
  18. Int.J.Pharm. v.90 Formation and antimycotic effect of cyclodextrin inclusion complexes of econazole and miconazole Pederson,M;Edelsten,M;Nielson,V.F;Scarpellini,A;Skytte,S;Slot,C
  19. Int.J.Pharm. v.59 The use of 2-hydroxypropyl-β-cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs Diezel,K;Estes,K.S;Brewster,M.E;Bodor,N.S;Derendorf,N
  20. Epilepsia(N.Y) v.36 New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-β-cyclodex-trin:tolerability and pharmacokinetics after intravenous injuction in comparison to a glycofurol-based formulation Locher,W;Hoenack,D;Richter,A;Schulz,H;Schuerer,M;Duesing,R;Brewster,M.E
  21. Int.J.Pharm v.189 New injectable melphalan formulations utilizing (SBE) 7m-β-CD of HP-β-CD Ma,D.Q;Rajewski,R.A;Stella,V.J
  22. Pharm.Res. v.14 Cyclodextrins:Their future in drug formulation and delivery Stella,V.J;Rajewsky,R.A
  23. Int.J.Pharm v.120 The effect of SBE4-β-CD on i.v.methylprednisolone pharmacokinetics in rats:comparison to a co-solvent solution and two water-soluble prodrugs Stella,V.J;Lee,H.K;Thompson,D.O
  24. Int.J.Pharm v.120 The effect of SBE4-β-CD on i.m.prednisolone pharmaco-kinetics and tissue damage in rabbits:comparison to a co-solvent solution and a water-soluble prodrugs Stella,V.J;Lee,H.K;Thompson,D.O
  25. Adv.Anal.Chem.Instrum v.4 Phase-solubility techniques Higuchi,T;Connors,K.A
  26. Int.J.Pharm v.163 The effect of water-soluble polymers on the aqueous solubility and complexing ability of β-cyclodextrin Loftsson,T;Friðiksdotir,H
  27. Am.J.Hosp.Pharm v.50 Stability of fluconazole in injectable solutions Hunt-Fugate,A.K;Hennesey,C.K;Kazarian,C.M
  28. Am.J.Hosp.Pharm v.50 Stability of fluconazole in an extemporaneously prepared oral liquid Yamreudeewong,W;Lopez-Anaya,A;Rappaport,H